Cerus Corporation (CERS) Financial Analysis & Valuation | Quarter Chart

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pa... more
Cerus Corporation operates as a biomedical products company. The company focuses on developing and c... more

Company facts

Reported company information and share structure.

Company Share structure
Market Cap$534.04MExchangeNASDAQ
SectorHealthcareIndustryMedical - Devices
CountryUSCEOVivek K. Jayaraman
IPO Date1997-01-31CAGR12.9%
Employees268Websitewww.cerus.com
Div. YieldPayout Ratio
Buy Back YieldTotal Yield
CERS chart loading...

Key metrics

Reported fundamentals and market-derived technical indicators.

Fundamentals Technicals
EV$703.56MP/E-52.89Forward P/E-530PEG
P/S1195.72P/B3805.12P/CF111400.58P/FCF-149444.79
Sales$227.78MSales 1Y18.32%Sales 3Y48.46%Sales 5Y113.54%
EPS$-0.05EPS 1Y-68.63%EPS 3Y-88.99%EPS 5Y-91.26%
Sales QoQ-4.09%EPS QoQSales QoQ Avg2.42%EPS QoQ Avg2797.01%
Gross Margin53.36%Operating Margin-3.71%Profit Margin-2.98%ROCE-7.07%
ROA-3%ROE-10%Altman Z Score-2.82Piotroski Score4
Current Ratio1.83Quick Ratio1.07Cash Ratio0.21Op. CF Ratio-0.03
Debt/Equity0.59Debt/Assets0.2Lt Debt/Equity0.12Lt Debt/Cap.0.11
Intrst Cov.-2.07Inventory Turnover1.61Asset Turnover1.11Receivables Turnover7.35
Enterprise Value$703.56MP/E Ratio-52.89
Forward P/E-530PEG Ratio
P/S Ratio1195.72P/B Ratio3805.12
P/CF Ratio111400.58P/FCF Ratio-149444.79
EPS$-0.05EPS Growth 1Y-68.63%
EPS Growth 3Y-88.99%EPS Growth 5Y-91.26%
Revenue Growth 1Y18.32%Gross Margin53.36%
Operating Margin-3.71%Profit Margin-2.98%
ROE-10%ROA-3%
ROCE-7.07%Current Ratio1.83
Quick Ratio1.07Cash Ratio0.21
Debt/Equity0.59Interest Coverage-2.07
Altman Z Score-2.82Piotroski Score4